ONO PHARMACEUTICAL CO
🇯🇵Japan
Clinical Trials
171
Active:40
Completed:82
Trial Phases
5 Phases
Phase 1:43
Phase 2:34
Phase 3:20
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (100 trials with phase data)• Click on a phase to view related trials
Phase 1
43 (43.0%)Phase 2
34 (34.0%)Phase 3
20 (20.0%)Not Applicable
2 (2.0%)Phase 4
1 (1.0%)A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants
Not Applicable
Not yet recruiting
- Conditions
- Primary Central Nervous System Lymphoma (PCNSL)
- Interventions
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT07198087
- Locations
- 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Orlando Clinical Research Center, Inc., Orlando, Florida, United States
A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)
Not yet recruiting
- Conditions
- Non Small Cell Lung Cancer NSCLC
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT07169708
Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Not Applicable
Not yet recruiting
- Conditions
- Relapsed/Refractory Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 132
- Registration Number
- NCT07104032
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 144
- Registration Number
- NCT06948448
ONO-4538 Study in Patients With Richter's Transformation
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 14
- Registration Number
- NCT06936943
- Locations
- 🇯🇵
Aichi Cancer Center, Nagoya, Aichi-ken, Japan
🇯🇵Kyusyu University Hospital, Fukuoka, Fukuoka, Japan
🇯🇵Hokkaido University Hospital, Sapporo, Hokkaido, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 21
- Next
News
No news found